BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC

NCT03791398 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Dose level 1 ONC201 625mg
DRUG: Dose level 2 ONC201 500mg
DRUG: Dose level 3 ONC201 375mg

Sponsor

Brown University

Collaborators

[object Object]
[object Object]
[object Object]